# Cartesian Therapeutics (RNAC) — Earnings

RNAC · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/rnac/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2025 |
| Period end | Jun 30, 2025 |
| EPS actual | $0.50 |
| EPS estimate | −$0.80 |
| EPS surprise | +162.27% |
| Revenue surprise | −67.91% |
| Revenue | $298,000.00 |
| Revenue estimate | $928,571.00 |
| Reported | Aug 7, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1453687/000145368725000099/rnac-20250630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2025 | Aug 7, 2025 | −$0.80 | $0.50 | 162.27% | $928,571.00 | $298,000.00 |
| Q1 2025 | May 8, 2025 | −$0.70 | −$0.68 | 3.04% | $916,667.00 | $1.1M |
| Q3 2024 | Nov 7, 2024 | −$0.80 | −$1.13 | -40.95% | $1.3M | $387,000.00 |
| Q2 2024 | Aug 8, 2024 | −$0.86 | $0.54 | 162.58% | $6.6M | $33.3M |
| Q1 2024 | May 8, 2024 | −$0.89 | −$10.50 | -1086.44% | $1.7M | $5.8M |
| Q4 2023 | Mar 7, 2024 | −$0.90 | −$2.17 | -141.11% | $2.5M | $8.3M |
| Q3 2023 | Nov 13, 2023 | −$2.34 | −$1.35 | 42.31% | $7.2M | $5.9M |
| Q2 2023 | Aug 17, 2023 | −$3.60 | −$2.10 | 41.67% | $5.6M | $5.2M |
| Q1 2023 | May 4, 2023 | −$2.60 | −$4.20 | -61.54% | $12.1M | $5.9M |
| Q4 2022 | Mar 2, 2023 | −$2.17 | $1.20 | 155.30% | $11.7M | $16.8M |
| Q3 2022 | Nov 3, 2022 | −$0.17 | −$1.50 | -775.15% | $25.2M | $20.7M |
| Q2 2022 | Aug 4, 2022 | −$2.27 | $1.80 | 179.25% | $13.8M | $39.3M |
| Q1 2022 | May 5, 2022 | −$3.35 | $6.90 | 305.91% | $12.1M | $34.0M |
| Q4 2021 | Mar 10, 2022 | −$2.46 | $3.00 | 222.20% | $17.2M | $29.9M |
| Q3 2021 | Nov 9, 2021 | −$2.23 | −$4.80 | -115.38% | $12.2M | $24.4M |
| Q2 2021 | Aug 12, 2021 | −$3.51 | $0.00 | 100.00% | $7.1M | $19.7M |
| Q1 2021 | May 13, 2021 | −$3.65 | −$6.60 | -80.82% | $6.3M | $11.1M |
| Q4 2020 | Mar 11, 2021 | −$3.73 | −$4.20 | -12.64% | $5.5M | $12.0M |
| Q3 2020 | Nov 5, 2020 | $2.96 | −$2.70 | -191.31% | $27.9M | $4.6M |
| Q2 2020 | Aug 6, 2020 | $0.58 | −$7.50 | -1390.21% | $25.0M | — |

## Frequently Asked Questions

### When did Cartesian Therapeutics (RNAC) last report earnings?

Cartesian Therapeutics last reported on Aug 7, 2025, covering fiscal Q2 2025.

### Did RNAC beat earnings estimates?

Yes. Cartesian Therapeutics reported EPS of $0.50 for Q2 2025 against a −$0.80 estimate — a 162.27% beat.

### How much revenue did RNAC report last quarter?

Cartesian Therapeutics reported $298,000.00 in revenue for Q2 2025, against a consensus estimate of $928,571.00.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).